Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines
NCT ID: NCT02840123
Last Updated: 2018-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
10 participants
INTERVENTIONAL
2016-06-30
2019-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Evaluate the nonspecific immune response generated in peripheral blood and Cerebral Spinal Fluid (CSF) by proposed treatment Evaluate the specific antitumor immunity response generated in peripheral blood and CSF Assess overall survival and progression free survival Correlate the neuroradiological changes with the clinical course and immune response generated in peripheral blood and CSF Quality of life evaluation
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dendritic Cell Vaccine for Patients With Brain Tumors
NCT01204684
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma
NCT04523688
Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma
NCT00576641
A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma
NCT02049489
Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
NCT00323115
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Autologous dendritic cells
Autologous dendritic cells
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Autologous dendritic cells
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged between 3 and 18 yo Lansky scale \>50 (Karnofsky for patients aged more than 16 yr)
* Life expectancy \> 8 weeks
* Preserved bone marrow function Normal hepatic and renal function
Exclusion Criteria
* Patient participation of other experimental study within the last 3 months
* Patient under antitumor treatment in the last 4 weeks
* Co-morbidity that does not allow the study treatment
* Patients requiring \> 2mg/day of dexamethasone treatment Corticoid-dependent patients
* Patients under uncontrolled infection
* Positive serologies of HIV, hepatitis C virus (HCV) or hepatitis B virus (HBV)
3 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut d'Investigacions Biomèdiques August Pi i Sunyer
OTHER
Fundació Sant Joan de Déu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Sant Joan de Deu
Esplugues de Llobregat, Barcelona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FSJD-DIPG-DC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.